Old Web
English
Sign In
Acemap
>
Paper
>
522P Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
522P Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
2021
Khobe Chandran
R. Grochot
S. Lai
Miriam Estevez Timon
Adam Sharp
Anna Minchom
Udai Banerji
J.S. de Bono
P Ursell
Juanita Lopez
Keywords:
early phase
Clinical trial
Oncology
Drug
Internal medicine
Medicine
Antibody
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]